The Effect of a High Fiber Diet and High-Intensity Interval Exercise in Patients With HFpEF

The Effect of a High Fiber Diet and High-Intensity Interval Exercise in Patients With Heart Failure With Preserved Ejection Fraction

This study is trying to find out how best to improve common measures of health and survival in those diagnosed with heart failure with preserved ejection fraction (HFpEF) through the implementation of 4 weeks of an exercise training program consisting of high intensity interval training, dietary approaches to stop hypertension (DASH diet), or a combination of the two. Currently there are not established guidelines that have been shown to improve clinical end points in those with this HFpEF.

Study Overview

• Status: Recruiting
• Conditions: Heart Failure With Preserved Ejection Fraction
• Intervention / Treatment: Behavioral: High Intensity Interval Exercise; Behavioral: Dietary Approaches to Stop Hypertension (DASH) Diet; Behavioral: Exercise + DASH Diet

Detailed Description

In the face of a rapidly growing population of older, HFpEF patients, there remains a need to identify ideal rehabilitative therapies to enhance improvements in the physical function of these patients. Pharmacological trials in this population have been characterized by a failure to significantly improve exercise tolerance and hard clinical outcomes and this is likely due to their singular cardiovascular focus. Exercise appears to be a promising intervention to improve cardiorespiratory fitness and reduce cardiovascular risk. Further, evidence-based dietary guidelines for patients with heart failure are lacking. Although a high-protein, low-carbohydrate diet is associated with improvements in traditional CV risk markers in patients with heart failure, it may raise cardiovascular risk in this population by adversely affecting endothelial function, increasing susceptibility to myocardial ischemia, and by inducing a pro-inflammatory state due to increased bacterial and LPS translocation through the ischemic gut. Thus, the investigators will explore the effects of the high-carbohydrate, high-fiber DASH diet due to its potential to have salutary effects on vascular risk in this population. In this study, the investigators will examine the singular and combined effects of exercise and a DASH diet in patients with HFpEF on markers of cardiovascular risk.

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Siddhartha S Angadi, PhD; Phone Number: 434-243-7466; Email: ssa2w@virginia.edu
• Study Contact Backup: Name: Nathan Weeldreyer, MS; Phone Number: 434-243-8677; Email: nw8ky@virginia.edu

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • Recruiting
      • University of Virginia University Hospital
      • Contact: Nathan Weeldreyer, MS; Phone Number: 434-243-8677; Email: nw8ky@virginia.edu
      • Contact: Siddhartha S Angadi, PhD; Email: ssa2w@virginia.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ≥40 years of age
• Diagnosed with heart failure with preserved ejection fraction
• NYHA class II-III symptoms
• Physician clearance to undergo exercise training
• Physician clearance to consume DASH diet
• Complete COVID-19 vaccination status

Exclusion Criteria:

• Unstable angina
• Myocardial infarction in the past 4 weeks
• Uncompensated heart failure
• NYHA class IV symptoms
• Complex ventricular arrhythmias
• Musculoskeletal contraindications to stationary bicycling exercise
• Symptomatic severe aortic stenosis
• Acute pulmonary embolus
• Acute myocarditis
• Uncontrolled hypertension
• Medication non-compliance
• Unable to follow DASH diet
• Food allergies (Nuts, wheat)
• Pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High Intensity Interval Exercise; Enrolled patients will perform supervised exercise on 3 nonconsecutive days of the week for 4 weeks.	Behavioral: High Intensity Interval Exercise; Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel. Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2. Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same.
Experimental: Dietary Approaches to Stop Hypertension (DASH) Diet; Enrolled patients will have all of their food prepared for them by a registered dietician for the duration of the study period. The diet will consist of a high fiber content DASH diet.	Behavioral: Dietary Approaches to Stop Hypertension (DASH) Diet; Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
Experimental: Exercise + DASH Diet; Enrolled subjects will undergo both the exercise training visits and be provided with the DASH diet.	Behavioral: Exercise + DASH Diet; Patients will undergo both the exercise training intervention and DASH diet as explained above.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VO2peak	Change in VO2peak (L/min) measured pre- and post-intervention	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diastolic Function	E' and A' (cm/s) will be used to calculate the E'/A' ratio to assess for diastolic dysfunction and be measured by echocardiogram pre- and post-intervention	4 weeks
Ejection Fraction	Ejection fraction (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram pre- and post-intervention	4 weeks
Global Longitudinal Strain	Global longitudinal strain (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram pre- and post-intervention	4 weeks
Blood pressure	Changes in measures of central and brachial blood pressure (mmHg) at pre- and post-intervention	4 weeks
Carotid-Femoral Pulse Wave Velocity	Changes in arterial stiffness as measured by carotid-femoral pulse wave velocity (m/s) at pre- and post-intervention	4 weeks
Body Composition	Changes in lean and fat mass (grams) will be measured via dual-energy x-ray absorptiometry pre-and post-intervention	4 weeks
Physical Activity Enjoyment Scale	Subject enjoyment of exercise will be measured using the Physical Activity Enjoyment Scale. This is an 18 item questionnaire which assess how subjects feel about the exercise they have been performing. Questions are scored using a 7-point likert scale	Immediately after the intervention
Minnesota Living with Heart Failure Questionnaire	Disease specific quality of life will be measured using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). he MLHFQ consists of 21 items that assess physical and emotional domains. Each item/question is scored on a 0-5 Likert scale.	4 weeks
Epworth Sleepiness Questionnaire	The Epworth sleepiness questionnaire is an 8 item questionnaire that measures how likely someone would be to fall asleep in 8 different scenarios. Each item is graded on a 4 point likert scale ranging from "would never nod off" to "high chance of nodding off".	4 weeks
Pittsburgh Sleep Quality Index	Sleep quality and sleep disturbances over the pervious month will be measured with the Pittsburgh sleep quality index (PSQI). The PSQI include 19 item self directed questions which look at a measures of sleep quality and a disturbances. It also includes 5 questions to be answered by a roommate (if available) regarding the patients sleep habits.	4 weeks
Circadian Type Questionnaire	The Circadian Type Questionnaire is an 19 item VAS that is used to assess someones ability to change their sleeping habits.	4 weeks
Sleep Apnea	Changes in sleep apnea will be measured using a WatchPAT device. This device measured finger peripheral arterial tone and measures arterial volume changes in the finger. This reflect changes in sympathetic tone and is associated with sleep disordered breathing.	4 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
NTproBNP	Assess changes in NTproBNP (pg/ml) as a biomarker of myocardial strain at pre- and post-intervention	4 weeks
Inflammation	C-reactive protein (mg/dl) will be used as a biomarker for inflammation to be measured pre- and post-intervention	4 weeks
Lipids	A lipid panel will be performed to measure total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoprotein (mg/dl) to assess changes in cardiometabolic health pre- and post-intervention	4 weeks
Insulin	Fasting insulin levels (U/ml) will be tested to assess changes in cardiometabolic health pre- and post-intervention	4 weeks
Fasting Blood Glucose	Fasting blood glucose levels (mg/dl) will be tested to assess changes in cardiometabolic health pre- and post-intervention	4 weeks
Endothelin-1	Arterial vasoconstrictor tone will be assessed by serum endothelin-1 (pg/mL) at pre- and post-intervention.	4 weeks
Lipopolysaccharide	Gut mucosal health and inflammation as measured by plasma Lipopolysaccharides (ng/mL) pre- and post-intervention	4 weeks
Trimethylamine-N-oxide	Trimethylamine-N-oxide (µM) will be used to assess gut mucosal health and inflammation pre- and post-intervention	4 weeks

Collaborators and Investigators

• Sponsor: University of Virginia
• Collaborators: Grain Foods Foundation
• Investigators: Principal Investigator: Siddhartha S Angadi, PhD, University of Virginia

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2022
• Primary Completion (Anticipated): March 1, 2024
• Study Completion (Anticipated): March 1, 2025

Study Registration Dates

• First Submitted: January 31, 2022
• First Submitted That Met QC Criteria: February 10, 2022
• First Posted (Actual): February 11, 2022

Study Record Updates

• Last Update Posted (Estimate): February 23, 2023
• Last Update Submitted That Met QC Criteria: February 22, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: heart failure; HIIT; DASH; HFpEF; High Fiber
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: HSR210393

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Deidentified data will be shared on request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No